共 157 条
- [1] Farré N(2017)Real world heart failure epidemiology and outcome: a population-based analysis of 88,195 patients PLoS ONE 12 e0172745-2183
- [2] Vela E(2004)Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment o reduction in mortality and morbidity (CHARM) program Circulation 110 2180-1405
- [3] Clèries M(2010)Mode of death in patients with heart failure and a preserved ejection fraction. Results from the irbesartan in heart failure with preserved ejection fraction study (I-preserve) trial Circulation 121 1393-21
- [4] Bustins M(2011)Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 11-1392
- [5] Cainzos-Achirica M(2014)Spironolactone form heart failure with preserved ejection fraction N Engl J Med 370 1383-1997
- [6] Enjuanes C(2015)Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients Eur Heart J 36 1990-1229
- [7] Solomon SD(2012)Why and how do elderly patients with heart failure die? Insights from the TIME-CHF study Eur J Heart Fail 14 1218-569
- [8] Wang D(2017)Mode of death in heart failure with preserved ejection fraction J Am Coll Cardiol 69 556-1669
- [9] Finn P(2012)Mode of death in patients with heart failure and reduce vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients Circ J 76 1662-97
- [10] Skali H(2008)Death in heart failure. A community perspective Circ Heart Fail 1 91-43